SOLENO THERAPEUTICS INC: 10-K filed 2015-03-13

Name: SOLENO THERAPEUTICS INC: 10-K filed 2015-03-13
Creator: SOLENO THERAPEUTICS INC

What SOLENO THERAPEUTICS INC reported in its annual report filed 2015-03-13 (fiscal FY 2014): 26 published measures, 51 facts as tagged in accession 0001193125-15-091006.

This filing

Form: 10-K (annual report)
Filed: 2015-03-13
Fiscal period: fiscal FY 2014
Accession: 0001193125-15-091006 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SOLENO THERAPEUTICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-12-31	8,395,925	USD
At 2013-12-31	1,586,691	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2014-12-31	-10,332,591	USD
At 2013-12-31	-37,864,463	USD
At 2012-12-31	-34,195,637	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-12-31	7,956,710	USD
At 2013-12-31	1,268,770	USD
At 2012-12-31	2,155,262	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-13,874,513	USD	365
2013-01-01 to 2013-12-31	-3,707,243	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	30,683	USD	365
2013-01-01 to 2013-12-31	1,274	USD	365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2013-01-01 to 2013-12-31	3,000,000	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-12-31	-70,975,024	USD
At 2013-12-31	-57,100,511	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	0	USD	365
2013-01-01 to 2013-12-31	0	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-12-31	57,607	USD
At 2013-12-31	63,167	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-5,159,729	USD	365
2013-01-01 to 2013-12-31	-846,783	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-12-31	8,338,318	USD
At 2013-12-31	1,523,524	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	4,130,394	USD	365
2013-01-01 to 2013-12-31	2,860,267	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-12-31	1,289,785	USD
At 2013-12-31	14,178,229	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2014-12-31	986,799	USD
At 2013-12-31	57,721	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2013-12-31	149,605	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	5,159,729	USD	365
2013-01-01 to 2013-12-31	3,846,783	USD	365

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2014-12-31	109,336	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	2,242,216	USD	365
2013-01-01 to 2013-12-31	2,379,832	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit
At 2014-12-31	6,769,106	shares
At 2014-11-18	535,685	shares
At 2013-12-31	535,685	shares

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2014-12-31	252,272	USD
At 2013-12-31	85,149	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2014-12-31	0	USD
At 2013-12-31	0	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	2,665,154	USD	365
2013-01-01 to 2013-12-31	1,466,951	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-4,585,475	USD	365
2013-01-01 to 2013-12-31	-1,965	USD	365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	-149,605	USD	365
2013-01-01 to 2013-12-31	149,605	USD	365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	109,336	USD	365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	353,897	USD	365
2013-01-01 to 2013-12-31	-161,803	USD	365

Inspect the source

Entity: SOLENO THERAPEUTICS INC / CIK 0001484565
Captured: 2026-09-21T17:20:12.023Z
SEC response SHA-256: 3eed7e55b763cfbacdaaf2e3553cf5147bbeb58f81f4e78fff7d779dd5ed6d44

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001484565.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))